COVID-19 Experience in Hemodialysis Patients: A Cue for Therapeutic Heparin-Based Strategies? | Zendy

Antonio Rosario Pisani | Zendy; Manuela Rizzo | Zendy; Valentina Angelucci | Zendy; Eleonora Riccio | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

COVID-19 Experience in Hemodialysis Patients: A Cue for Therapeutic Heparin-Based Strategies?

Author(s) -

Antonio Rosario Pisani,

Manuela Rizzo,

Valentina Angelucci,

Eleonora Riccio

Publication year - 2020

Publication title -

the nephron journals/nephron journals

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.951

H-Index - 72

eISSN - 2235-3186

pISSN - 1660-8151

DOI - 10.1159/000508638

Subject(s) - medicine , heparin , anticoagulant , covid-19 , hemodialysis , intensive care medicine , anticoagulant therapy , disease , infectious disease (medical specialty)

In our opinion, the use of heparin could play a crucial role in these patients. In fact, recent studies have shown that heparin, the most commonly used anticoagulant during HD procedures, had anti-inflammatory properties and a direct antiviral action, due to its ability to prevent SARS-CoV-2 pseudovirus entry into host cells. These activities, together with its anticoagulant action, could explain the ability of heparin to ameliorate COVID-19 clinical course.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research